Acquired bla carried by a conjugative transposon or duplicated intrinsic bla mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates.

OBJECTIVES

Elizabethkingia spp. are resistant to multiple antibiotics. This study aimed to determine in vitro and in vivo activities of cefiderocol against Elizabethkingia spp. and to investigate resistance mechanisms.

METHODS

Bloodstream isolates were collected from four hospitals. In vitro and in vivo activities were determined using broth microdilution and the wax moth model, respectively. Genome comparison and gene editing were used to confirm the contribution of target genes. Conjugation experiments and serial passage were used to determine transferability and stability, respectively. A MIC of ≤4 mg/L was designated as the susceptibility breakpoint.

RESULTS

Among 228 non-duplicated isolates, 226 exhibited a MIC of ≤4 mg/L with MIC of 1/2 mg/L. Two isolates had a MIC of 128 mg/L; both patients had multiple comorbidities, were ventilator-dependent and had not received cefiderocol previously. Resistance was attributable to acquisition of bla, carried by a conjugative transposon from Prevotella jejuni, and duplication of intrinsic bla, which led to its overexpression. tetQ coexisted with bla in this conjugative transposon and minocycline facilitated its transfer among E. anophelis. Antibiotics prescribed for source patients did not induce bla duplication. The stabilities of bla and double bla were 100% and > 90%, respectively, after 10-day serial passage. Cefiderocol failed to rescue moth larvae infected with resistant strains, but removal of resistance mechanisms restored in vivo efficacy.

CONCLUSIONS

Cefiderocol was in vitro and in vivo active against Elizabethkingia spp. but resistance may emerge due to the availability, transferability, and/or stability of resistance mechanisms.